Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myel...
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
About this item
Full title
Author / Creator
Rausch, Christian , Rothenberg-Thurley, Maja , Dufour, Annika , Schneider, Stephanie , Gittinger, Hanna , Sauerland, Cristina , Görlich, Dennis , Krug, Utz , Berdel, Wolfgang E. , Woermann, Bernhard J. , Hiddemann, Wolfgang , Braess, Jan , von Bergwelt-Baildon, Michael , Spiekermann, Karsten , Herold, Tobias and Metzeler, Klaus H.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The revised 2022 European LeukemiaNet (ELN) AML risk stratification system requires validation in large, homogeneously treated cohorts. We studied 1118 newly diagnosed AML patients (median age, 58 years; range, 18–86 years) who received cytarabine-based induction chemotherapy between 1999 and 2012 and compared ELN-2022 to the previous ELN-2017 risk...
Alternative Titles
Full title
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
Authors, Artists and Contributors
Author / Creator
Rothenberg-Thurley, Maja
Dufour, Annika
Schneider, Stephanie
Gittinger, Hanna
Sauerland, Cristina
Görlich, Dennis
Krug, Utz
Berdel, Wolfgang E.
Woermann, Bernhard J.
Hiddemann, Wolfgang
Braess, Jan
von Bergwelt-Baildon, Michael
Spiekermann, Karsten
Herold, Tobias
Metzeler, Klaus H.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10244159
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10244159
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/s41375-023-01884-2
